The Metro Montréal Life Sciences Cluster Presentation by: Michel Leblanc, Vice-President, Life Sciences, Montréal International and Louise Proulx, Vice-Principal.

Slides:



Advertisements
Similar presentations
City of Aarhus Mayors Department Business and City Development Second cities and economic growth Jan Beyer Schmidt-Sørensen City of Aarhus OPEN DAYS 2009.
Advertisements

Life Science Cluster in Krakow
EAC HIGHER EDUCATION POLICY
Pakistan Services Roadmap ~ Implementation Priorities.
Advancing Alternative Energy Technologies Glenn MacDonell Director, Energy Industry Canada Workshop on Alternatives to Conventional Generation Technologies.
Copyright © 2010 WEConnect International, Inc., All Rights Reserved Presentation by Virginia Littlejohn, CEO and Co-Founder of Quantum Leaps, Inc. and.
1 CLEVELAND The Nation’s New Healthcare Innovation Destination 2011.
Austin technology incubator New Strategies for the 21 st Century Incubator Presented by: Erin Defosse Former Director Austin Technology Incubator REV XXXX.
High Impact Implementation for an Innovation-Driven Economy The Texas Industry Cluster Initiative.
An Overview of the Canadian Pharmaceutical Industry
New Media Innovation Centre (NewMIC) AN INDUSTRY - UNIVERSITY - GOVERNMENT COLLABORATION.
Strategic Plan - Draft June 23, Outline Mission/Vision/Goals of Alliance Summary: Strategic Plan Recommendations Part I: Institute of Health Science.
2015. MITA. All rights reserved.````` Lithuanian Country Report Gintarė Narakienė The Agency for Science, Innovation and Technology.
Innovation, Colleges and Applied Research ACCC College and Institute Applied Research Symposium (February 12-13, 2004)
Securing Tomorrow’s Prosperity University of Calgary – Faculty of Engineering Planning Workshop May 10, 2005 Rick Sloan Assistant Deputy Minister Industry.
January 3, 2003 Kevin Rakin President and Chief Executive Officer Kevin Rakin President and Chief Executive Officer Economic Summit and Outlook 2003.
Updated Mission Stimulate the Québec economy by making strategic investments that will benefit Québec workers and businesses alike To invest.
Knowledge Translation: A View from a National Policy Perspective KU-02 Conference Oxford, England July 2, 2002.
Strengths and Gaps in the Canadian Vaccine Landscape: a biotech perspective Nathalie Charland, PhD Sr. Director, Scientific liaisons Vaccine Innovation.
N O R T H C A R O L I N A B I O T E C H N O L O G Y C E N T E R North Carolina – Leading Global Hub for Agricultural Biotechnology NCBiotech - AgBiotech.
Centre for Innovation, Technology Transfer and University Development Jagiellonian University Centre for Innovation, Technology Transfer and University.
National innovation strategies and policies - Republic of Slovenia Dr. Klemen Grošelj SIPO Novi Sad,
1 INVESTING IN ARIZONA’S UNIVERSITIES INVESTING IN ARIZONA’S UNIVERSITIES Presentation by The University of Arizona, May 5, 2008.
Biotech Clusters in British Columbia. To be the catalyst for a life sciences cluster of genomics-related research institutions and companies working together.
Triple Helix IX International Conference Stanford University Triple Helix IX International Conference Stanford University History Planning Future Research.
Universities and Governments: The Commercialization & Innovation Agenda Sitting Beside the Elephant –AUTM Metrics and Performance Anxiety AUCC and Federal.
Horizon 2020 Some reflections from a business perspective Dr Jan-Eric Sundgren Executive Vice President, Volvo Group Chairman of the Associate Group European.
The Canadian Chamber of Commerce Canada’s Opportunities and Barriers for Success May 12, 2011 Toronto, Ontario Chris Gray Director, Innovation Policy
Paul Maguire Enterprise Ireland Biotechnology Commercialisation in Ireland - Looking to the Future Federal Lab Consortium (FLC) / Mid-Atlantic Region (MAR)
Mid-Shore CEDS Committee Meeting January 6, 2010.
SCIENCE & TECHNOLOGY Qualifying young researchers for the knowledge society SCTRE, AER Peer Review, 23 Nov
Foreign Direct Investment: attract more to benefit more Khalil Hamdani Istanbul, 20 November 2013.
Innovation Systems Research Network MCRI Theme III: Social Inclusion and Civic Engagement David A. Wolfe, Ph.D. Program on Globalization and Regional Innovation.
Nathan Tinker Executive Director New York Biotechnology Association New York BizBio 2009 Fighting for a Healthy Biotech Industry.
Rónán Ó Dubhghaill, Ext June 2012 Draft University Strategic Plan Overview Rónán Ó Dubhghaill Director of Strategic Planning & Institutional.
©The University of Alabama in Huntsville The North Alabama Region A Globally Competitive Community Industry Clusters The.
Global Strategic Plan Overview. 5 Pillar Framework The Movement has validated our 5 Pillar approach, so we must invest in a balanced portfolio that leads.
PUBLIC R&D POLICY IN RUSSIA Restructuring Government S&T Institutions Tatiana Kuznetsova STATE UNIVERSITY – HIGHER SCHOOL OF ECONOMICS Institute for Statistical.
SMEs in Canada Facts Federal Role. 1 Outline Overview of SMEs in Canada Roles of Government.
Entrepreneurship in Dane County Edward Clarke Strategic Innovation Office MATC.
Investing in the State of Innovation International Seminar on Knowledge and Innovation 1 October, 2013 Creating a High-Performance Innovation Ecosystem:
MEDICAL INNOVATION March What Are The Public Health Benefits of Medical Innovation? Breakthrough medicines New devices Innovative medical procedures.
Forward Oklahoma City IV March 30, FORWARD OKLAHOMA CITY AIMS TO: Create Quality Jobs Increase Capital Investment Retain Existing Business Improve.
Transforming the Tech Valley Workforce Region A Blueprint From Traditional Manufacturing to Globally Competitive Advanced Manufacturing and Technology.
Presentation by Robert Keating Assistant Deputy Minister Bilateral Affairs Ministère des Relations internationales Canada-United States.
Christo van Niekerk, M.D. Senior Director, Clinical Development Pretoria, South Africa Innovating TB Treatment: Opportunities for Private Sector Engagement.
September 25, AGENDA 1. Columbus The Creation of Columbus Key Strategies and Metrics 4. Continued Evolution 5. Progress.
Luxembourg – 6 March 2014 Industrial Changes in the European Pharmaceutical Sector IndustriAll Pharmaceutical Committee Enrico Gibellieri - EESC/CCMI Jean-François.
Committee Meeting, June 9, 2008 Strategic Institutional Research Plan.
Australian Injury & Disability Insurance Network AIIN Health Special Interest Group & ICT Geelong November
Working with Croydon Nick Royle, Head of North America FDI Team.
Presentation to Membership. A Recap of Our Process February 2009: Decision to renew strategic plan March 2009: Engagement of Berlin, Eaton.
LLNs and Higher Level Skills: A Northwest Perspective Dr Lis Smith, NWDA.
Toronto’s Agenda for Prosperity Presentation to YEP/TTB Information Session November 13, 2009.
Prepared by Collaborative Economics. EXECUTIVE SUMMARY  San Diego is participating in a new global innovation economy  San Diego’s global reach has.
The Ottawa Life Science – Biotech Cluster Robert Dalpé Dép. de science politique and CIRST Université de Montréal ISRN Vancouver May 2004.
Date: in 12 pts Digital Entrepreneurship The EU vision, strategy and actions First meeting of the Member States Board on Digital Entrepreneurship Brussels,
0 Dr. Peter Frey │ SOLARVALLEY MITTELDEUTSCHLAND │ Paris, 14. April 2011 PV production in Germany - threats & opportunities Dr. Peter Frey, CEO Solar Valley.
Economy Sub-Committee Meeting 22nd April 2013 Jonathan Wilson, Programme Manager Scottish Enterprise Economy Sub-Committee Meeting 22nd April 2013 Jonathan.
Balancing Objectives and Needs of Industry and Academia: the Role of Government Presentation by Mary Cryan Meeting of National Councils for S&T Policy.
June 23, 2016 Organizational Overview. 2 Automation Federation Background A fragmented community of automation professional associations and societies.
Science, Technology, Engineering, and Innovation as Instruments for Enhancing Competitiveness Organization of American States Meeting of Ministers and.
A 20-year success story: The Canada Foundation for Innovation the transformational impacts of sustained investments in research infrastructure Expanding.
UNCLASSIFIED Lift the living standards and wellbeing of all Victorians by sustainably growing Victoria’s economy and employment and by working with the.
PRESENTATION TITLE | DATE STEM Best Practices Conference Industry Strand – Skills & Career Paths Kelly Slone President & CEO, BioUtah June 21, 2016.
The Demand-Driven Workforce Investment System
Toronto region is the only growing metro region in north America
UCD School of Medicine & Medical Science
INNOVATION SUPERCLUSTERS INITIATIVE
Bertelsmann Education Strategy
Presentation transcript:

The Metro Montréal Life Sciences Cluster Presentation by: Michel Leblanc, Vice-President, Life Sciences, Montréal International and Louise Proulx, Vice-Principal (Research), McGill University At the International Conference on Technology Clusters November 7- 8, 2003

Greater Montréal  Pop : 3.5 million, 47 % of Québec and 11% of Canada  GNP : more than $120 Billion, 50 % of Québec and 10% of Canada; a very diversified economy  63 cities, total area over KM 2

Some numbers about the Cluster Life Sciences includes Pharmaceuticals, Biotechnologies, Medical devices, Bio-computing, Bio-genomics, Agri-Food … 274 companies and 125 research organizations direct jobs, compared to at the beginning of 2002 –A net increase of new jobs, or 8 % – in the private sector and in research organizations Presence of a solid core of large pharmaceutical multinationals Full continuum along the chain of value creation Fundamental research Development and clinical trials Production and commercialization

The Montréal Life Sciences Cluster

The Importance of Foreign Investments 50 % of the private sector jobs Nine of the ten largest employers –Merck Frosst Canada, employees –Services pharma MDS, employees –Clin Trials BioRecherche, employees –Wyeth Canada, employees –Laboratoires Abbott, 750 employees –Aventis Pharma, 750 employees –Pfizer, 650 employees –Bristol-Myers Squibb, 530 employees –Schering, 400 employees –Novartis Pharma, 350 employees

Our Approach Porter’s studies on innovative regions and the relevance of the concept of clusters for large metro areas We adopted a participative approach  Coordinated by a private not-for-profit economic development agency, Montréal International,  With the participation of the private sector, research centres, universities and training colleges, and governments Quick response  Mobilization : Sept April 2002  Approval of a vision and an action plan : April 2002  Implementation : Summer 2002

A common vision, ambitious... yet realistic « To Position Greater Montréal as a Dynamic World Leader in the Life Sciences » Creating at least new direct jobs by the year 2010 (Which implies doubling the observed natural job growth rate of the Cluster)

The Action Plan Includes « across the board » initiatives –Coordination and mobilization structure –Actions to improve and expand training capabilities –Measures to reinforce business creation and development –Initiative to create a powerful distinct image and launch an international marketing strategy... And specific initiatives to reinforce local centres of excellence –Strengthening the development of five existing centres and an emerging one –Integration of university hospitals within the core of the Cluster development

Coordination and Mobilization through the Montréal Metro Life Sciences Committee Meets 4 times a year Includes –Majority from the private sector : 5 CEOs (or equivalent) of large pharmas; 7 CEOs of Biotech and medical devices; 2 directors of business associations –Government : 2 deputy ministers, Canada and Québec –Institutions : 4 provosts (or equivalent), from each of the universities of the area; 1 Director of a training college representing all colleges in the area; 2 Directors of public research institutes –Other partners : 2 managers of venture cap. ; 2 directors of centres of excellence; the CEO and the V-P Life Sciences of Montréal International

Tradition of academic excellence and a history of research and innovation, which draw and help retain world class researchers Opportunities for the commercialization of innovative academic research Favourable business and investment climate Metro Montréal’s Life Sciences Cluster: Recipe for Success

Metro Montréal: Intellectual Capital of North America … Of the 30 largest cities in North America, Metro Montréal has the highest number of university students per capita A metropolis with world-class universities and excellent colleges: four Montréal universities offer specialized life sciences programs … And A Dynamic Environment for Training High Calibre Personnel A total of more than 6,700 students are presently enrolled in university-level life sciences programs in Metro Montréal More than 1,150 university health sciences degrees are awarded each year in Metro Montréal

Metro Montréal: A Research-intensive Metropolis Thousands of researchers conducting fundamental research in life sciences at: –More than 125 university centres, affiliated hospital research institutes or labs in Metro Montréal Combined sponsored research income for Metro Montréal universities 1st place in Canada and ahead of Toronto area universities –$776M (McGill, UdeM, UQAM, Concordia) vs. $507M (Ryerson; UofT; York) National and international interuniversity research networks based here

Commercialization of Research Each university has an industry-university liaison office, providing services to protect intellectual property and to commercialize research results Innovative research translates into innovative products, services and novel therapies through licenses and the creation of spin-offs

Monitoring our progress Job creation above and beyond the target of per year Investment decisions in excess of $415 million in 2003 –DSM Biologics, expansion, $160 M –Ratiopharm, expansion, $80 M –Tyco Medical, expansion, $28 M –Aventis Pharma, expansion, $20 M –Draxis Pharma, expansion, $20 M –… Strategic decisions for the Cluster –Pfizer chooses to maintain its headquarters in Montréal after the integration of Pharmacia –Construction of Novartis’s new headquarters

Key challenges for (1) 1.To stimulate an environment conducive to the creation of private venture funds and the attraction of foreign venture capital 2.To preserve a favourable business climate for innovation in the pharmaceutical sector 3.To preserve our competitive advantage in human resources –Improve the training of specialized managers –Increase the appeal of scientific careers –Train more technicians

Key challenges for (2) 4.Adopt a marketing strategy for the Cluster itself (“branding”) 5.Reinforce research infrastructure and equipment –Consolidate the National Biotechnology Research Institute –Stimulate more synergy between businesses and our three University Hospitals –Encourage all possible synergy between public research and private partners